Last updated: 2026-09-14 12:31:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Altimmune, Inc. (ALT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.31, with a market capitalization of $636.07M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.56 to $6.44. This page covers its latest market performance, valuation, price trends and company information.
$636.07M | |
$3.27 | |
$44,550.00 | |
$1.51 | |
$3.27 | |
28.26K | |
4.47M | |
-- | |
$6.44 | |
$2.56 | |
-- | |
-- |
Altimmune, Inc. (ALT) is trading at $3.31 in pre-market trading as of 2026-09-14 12:29:00, up 1.35% ($0.04) from the previous close of $3.27
Pre-market trading shows how investors are pricing ALT before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Altimmune, Inc. (ALT) moved from $3.28 to $3.31, representing a gain of 1.04% ($0.03).
The stock traded between $3.10 and $3.55 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 3.83 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 19.4%
ALT is currently trading at $3.31, placing it 19.4% of the way from its 52-week low of $2.56 to its 52-week high of $6.44. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 57 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Altimmune, Inc. (ALT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.